Yu Deng

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo et al. · New England Journal of Medicine · 2018 · 3.7K citations · Full text

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Roy S. Herbst, Giuseppe Giaccone, Filippo de Marinis et al. · New England Journal of Medicine · 2020 · 1.6K citations · Full text

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Enriqueta Felip, Nasser K. Altorki, Caicun Zhou et al. · The Lancet · 2021 · 1.4K citations

Oncology, Adjuvant Chemotherapy, Pathology +6

m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade

Seungwon Yang, Jiangbo Wei, Yan‐Hong Cui et al. · Nature Communications · 2019 · 804 citations · Full text

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

Stephen V. Liu, Martin Reck, Aaron S. Mansfield et al. · Journal of Clinical Oncology · 2021 · 763 citations · Full text